FDA approves Sanofi's Infilbray for neurological symptoms of Gaucher disease type 3
- FDA approved Sanofi's Infilbray (venglustat) as the first treatment for neurological manifestations of Gaucher disease type 3.
- The once-daily oral drug is indicated for adults and pediatric patients weighing at least 15 kg.
- Regulatory reviews remain underway in the European Union, Japan and other jurisdictions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611181718OMX_____CNEWS_FR_GNW1001304388_fr) on November 18, 2026, and is solely responsible for the information contained therein.